Models of LRRK2-associated parkinson’s disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic causes of Parkinson’s disease (PD) and also one of the strongest genetic risk factors in sporadic PD. The LRRK2 protein contains a GTPase and a kinase domain and several protein-protein interaction domains. Both in vitro and in vivo assays in different model systems have provided tremendous insights into the molecular mechanisms underlying LRRK2-induced dopaminergic neurodegeneration. Among all the model systems, animal models are crucial tools to study the pathogenesis of human disease. How do the animal models recapitulate LRRK2-induced dopaminergic neuronal loss in human PD? To answer this question, this review focuses on the discussion of the animal models of LRRK2-associated PD including genetic-and viral-based models.

Original languageEnglish (US)
Title of host publicationAdvances in Neurobiology
PublisherSpringer New York LLC
Pages163-191
Number of pages29
Volume14
DOIs
StatePublished - Apr 1 2017

Publication series

NameAdvances in Neurobiology
Volume14
ISSN (Print)21905215

Fingerprint

Leucine
Parkinson Disease
Phosphotransferases
Animal Models
Animals
Protein Interaction Domains and Motifs
GTP Phosphohydrolases
Protein Kinases
Assays
Genes
Mutation
Proteins

Keywords

  • Animal models
  • LRRK2
  • Parkinson’s disease

ASJC Scopus subject areas

  • Biochemistry
  • Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience

Cite this

Xiong, Y., Dawson, T. M., & Dawson, V. (2017). Models of LRRK2-associated parkinson’s disease. In Advances in Neurobiology (Vol. 14, pp. 163-191). (Advances in Neurobiology; Vol. 14). Springer New York LLC. https://doi.org/10.1007/978-3-319-49969-7_9

Models of LRRK2-associated parkinson’s disease. / Xiong, Yulan; Dawson, Ted M; Dawson, Valina.

Advances in Neurobiology. Vol. 14 Springer New York LLC, 2017. p. 163-191 (Advances in Neurobiology; Vol. 14).

Research output: Chapter in Book/Report/Conference proceedingChapter

Xiong, Y, Dawson, TM & Dawson, V 2017, Models of LRRK2-associated parkinson’s disease. in Advances in Neurobiology. vol. 14, Advances in Neurobiology, vol. 14, Springer New York LLC, pp. 163-191. https://doi.org/10.1007/978-3-319-49969-7_9
Xiong Y, Dawson TM, Dawson V. Models of LRRK2-associated parkinson’s disease. In Advances in Neurobiology. Vol. 14. Springer New York LLC. 2017. p. 163-191. (Advances in Neurobiology). https://doi.org/10.1007/978-3-319-49969-7_9
Xiong, Yulan ; Dawson, Ted M ; Dawson, Valina. / Models of LRRK2-associated parkinson’s disease. Advances in Neurobiology. Vol. 14 Springer New York LLC, 2017. pp. 163-191 (Advances in Neurobiology).
@inbook{b3aceefe0da048c498c72bdc5958f892,
title = "Models of LRRK2-associated parkinson’s disease",
abstract = "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic causes of Parkinson’s disease (PD) and also one of the strongest genetic risk factors in sporadic PD. The LRRK2 protein contains a GTPase and a kinase domain and several protein-protein interaction domains. Both in vitro and in vivo assays in different model systems have provided tremendous insights into the molecular mechanisms underlying LRRK2-induced dopaminergic neurodegeneration. Among all the model systems, animal models are crucial tools to study the pathogenesis of human disease. How do the animal models recapitulate LRRK2-induced dopaminergic neuronal loss in human PD? To answer this question, this review focuses on the discussion of the animal models of LRRK2-associated PD including genetic-and viral-based models.",
keywords = "Animal models, LRRK2, Parkinson’s disease",
author = "Yulan Xiong and Dawson, {Ted M} and Valina Dawson",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/978-3-319-49969-7_9",
language = "English (US)",
volume = "14",
series = "Advances in Neurobiology",
publisher = "Springer New York LLC",
pages = "163--191",
booktitle = "Advances in Neurobiology",

}

TY - CHAP

T1 - Models of LRRK2-associated parkinson’s disease

AU - Xiong, Yulan

AU - Dawson, Ted M

AU - Dawson, Valina

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic causes of Parkinson’s disease (PD) and also one of the strongest genetic risk factors in sporadic PD. The LRRK2 protein contains a GTPase and a kinase domain and several protein-protein interaction domains. Both in vitro and in vivo assays in different model systems have provided tremendous insights into the molecular mechanisms underlying LRRK2-induced dopaminergic neurodegeneration. Among all the model systems, animal models are crucial tools to study the pathogenesis of human disease. How do the animal models recapitulate LRRK2-induced dopaminergic neuronal loss in human PD? To answer this question, this review focuses on the discussion of the animal models of LRRK2-associated PD including genetic-and viral-based models.

AB - Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic causes of Parkinson’s disease (PD) and also one of the strongest genetic risk factors in sporadic PD. The LRRK2 protein contains a GTPase and a kinase domain and several protein-protein interaction domains. Both in vitro and in vivo assays in different model systems have provided tremendous insights into the molecular mechanisms underlying LRRK2-induced dopaminergic neurodegeneration. Among all the model systems, animal models are crucial tools to study the pathogenesis of human disease. How do the animal models recapitulate LRRK2-induced dopaminergic neuronal loss in human PD? To answer this question, this review focuses on the discussion of the animal models of LRRK2-associated PD including genetic-and viral-based models.

KW - Animal models

KW - LRRK2

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85017103170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017103170&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-49969-7_9

DO - 10.1007/978-3-319-49969-7_9

M3 - Chapter

C2 - 28353284

AN - SCOPUS:85017103170

VL - 14

T3 - Advances in Neurobiology

SP - 163

EP - 191

BT - Advances in Neurobiology

PB - Springer New York LLC

ER -